| Literature DB >> 34128484 |
Eva Compérat1,2, Mahul B Amin3,4, Jonathan I Epstein5,6,7, Donna E Hansel8, Gladell Paner9, Hikmat Al-Ahmadie5, Larry True10, Dilek Baydar11, Trinity Bivalacqua7, Fadi Brimo12, Liang Cheng13, John Cheville14, Guido Dalbagni6, Sara Falzarano15, Jennifer Gordetsky16,17, Charles Guo18, Sounak Gupta14, Ondrej Hes19, Gopa Iyer20, Seema Kaushal21, Lakshmi Kunju22, Cristina Magi-Galluzzi23, Andres Matoso5,6, Jesse McKenney24, George J Netto23, Adeboye O Osunkoya5,25, Chin Chen Pan26, Kristina Pivovarcikova19, Maria R Raspollini27, Henning Reis28, Jonathan Rosenberg29, Morgan Roupret30, Rajal B Shah5,31, Shahrokh F Shariat32, Kiril Trpkov33, Veronika Weyerer34, Ming Zhou35, Victor Reuter5.
Abstract
The Genitourinary Pathology Society (GUPS) undertook a critical review of the recent advances in bladder cancer focusing on important topics of high interest for the practicing surgical pathologist and urologist. This review represents the second of 2 manuscripts ensuing from this effort. Herein, we address the effective reporting of bladder cancer, focusing particularly on newly published data since the last 2016 World Health Organization (WHO) classification. In addition, this review focuses on the importance of reporting bladder cancer with divergent differentiation and variant (subtypes of urothelial carcinoma) histologies and the potential impact on patient care. We provide new recommendations for reporting pT1 staging in diagnostic pathology. Furthermore, we explore molecular evolution and classification, emphasizing aspects that impact the understanding of important concepts relevant to reporting and management of patients.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34128484 DOI: 10.1097/PAP.0000000000000309
Source DB: PubMed Journal: Adv Anat Pathol ISSN: 1072-4109 Impact factor: 3.875